New drug combo shows promise in preventing transplant complications

NCT ID NCT03605927

Completed Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 29 times

Summary

This early-phase study tested whether adding a drug called BMS-986004 (which blocks CD40-L) to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD is a serious condition where donor immune cells attack the patient's body. The main goal was to see how many patients developed moderate-to-severe GVHD within 100 days after transplant. Participants had to have a well-matched donor and be in relatively good health. The study is complete, and results help guide future research on preventing GVHD.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.

GRAFT VERSUS HOST DISEASE GVHD GVHD GVHD, ACUTE GVHD, ACUTE